Combination chemotherapy for children with hard-to-treat solid tumors
Part of Cancer clinical trials.
This trial tests a combination of three chemotherapy drugs (irinotecan, temozolomide, and vincristine) in children and teens whose solid tumors have come back or stopped responding to standard treatment. The goal is to see if this combination can help shrink or control the tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 12 and 18 years old.
- You must have a solid tumor that has come back, gotten worse, or not responded to standard treatment.
- You need to be well enough to perform daily activities, with a score of at least 50 on a standard physical condition scale.
- Your heart must be working well, as shown by normal heart tests and no recent heart problems.
- You must have fully recovered from the side effects of previous cancer treatments, with a waiting period after certain medications or therapies.
- Your blood counts and organ function (kidney and liver) must meet minimum levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four drugs (liposomal irinotecan, vincristine, temozolomide, and anlotinib) for children and teens whose solid tumors have come back or haven't responded to standard treatment. The goal is to see if this drug mix can shrink or control the tumors.
This trial tests a new combination of chemotherapy drugs (irinotecan, temozolomide, and vincristine) for children whose solid tumors have come back or not responded to standard treatment. It aims to see if a specific gene test can help doctors choose the right dose of irinotecan to reduce side effects.
This trial tests a new combination of three chemotherapy drugs (eribulin, irinotecan, and temozolomide) for children and young adults whose solid tumors have come back or not responded to standard treatment. The goal is to see if this combination is safe and effective.
This trial tests a combination of three drugs (VIM and VIT) for children and young adults whose soft tissue sarcoma has come back or not responded to previous treatments. The goal is to see if this new combination can help shrink or control the tumor.
This trial compares two treatment combinations—liposomal doxorubicin plus irinotecan versus a different chemotherapy plan—in children and teens whose rhabdomyosarcoma came back or did not respond. It aims to see which option works better and is safer for children who have had prior cancer treatment.
This trial tests a new combination of two chemotherapy drugs, liposomal irinotecan and cisplatin, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can help shrink tumors or slow their growth.
Hear when a new Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.